Breakthrough Menstrual Blood Test Detects Endometriosis In 10 Minutes

UNIVERSITY PARK, Pa. — A groundbreaking new diagnostic technology could transform how doctors detect endometriosis, a painful condition that affects millions of women worldwide and often goes undiagnosed for years. Researchers have developed an ultra-sensitive menstrual blood test using a cutting-edge two-dimensional material called borophene. The material can detect disease markers at concentrations far lower than current methods, potentially offering a new path to earlier, less invasive diagnosis.

Endometriosis affects roughly 10% of reproductive-age women, causing severe pelvic pain, heavy bleeding, and in many cases, infertility. The condition occurs when tissue similar to the uterine lining grows outside the uterus, but current diagnostic methods often require invasive procedures or expensive imaging that may miss early-stage disease. The average delay in endometriosis diagnosis spans eight to 12 years, leaving countless women suffering without answers.

How Borophene Technology Works for Medical Testing

Borophene is a single-atom-thick sheet of boron atoms arranged in a honeycomb structure. This two-dimensional material belongs to a family of ultra-thin substances that includes graphene, but borophene offers unique properties that make it particularly suited for medical testing.

The innovation out of Pennsylvania State University centers around a lateral flow immunoassay — essentially an advanced version of a pregnancy test — that can identify HMGB-1, a protein marker associated with endometriosis, in menstrual blood. What sets this technology apart is how the antibodies (the molecules that detect specific targets) are attached to the borophene surface.

Traditional diagnostic tests often struggle with antibody orientation, meaning the detection molecules might not be positioned optimally to capture their targets. By exposing antibodies to ultraviolet light for just 30 seconds, researchers can break specific chemical bonds within the antibodies, creating reactive sites that form strong bonds with the borophene surface. This process ensures the antibodies are oriented correctly, with their detection regions exposed and ready to capture HMGB-1 proteins.

Test Sensitivity Results Show Major Improvement

The researchers tested their borophene-based assay using menstrual blood spiked with known concentrations of HMGB-1, rather than samples from actual endometriosis patients. Even so, the test proved highly sensitive: it detected the protein at concentrations as low as 40 picograms per milliliter. In contrast, conventional lateral flow tests only yielded results at 240 picograms per milliliter, indicating a sixfold improvement in detection sensitivity. While the paper does not use percentage figures, this represents a substantial advance in detection capability. And importantly, the test produces results in just 10 minutes, without requiring any lab equipment.

Specificity testing revealed another crucial advantage: the new assay showed no false positives when exposed to common blood proteins like albumin and fibrinogen, ensuring accurate results without interference from other substances naturally present in menstrual blood.

Clinical Applications for Women’s Health Diagnostics

Current endometriosis diagnosis often relies on laparoscopic surgery, a minimally invasive but still surgical procedure that requires general anesthesia. Less invasive alternatives like MRI or ultrasound may miss early-stage disease or require expensive equipment not available in all healthcare settings.

This rapid turnaround could enable point-of-care testing in doctors’ offices or even at-home screening, dramatically improving access to endometriosis detection. While not addressed directly in the paper, the simplicity and speed of the test raise the possibility that future iterations could be incorporated into menstrual products, allowing for discreet, at-home monitoring of endometriosis biomarkers, especially in areas with limited access to gynecological care.

The ability to use menstrual blood rather than requiring a separate blood draw offers additional advantages. Menstrual blood collection is non-invasive and can be performed privately, potentially increasing participation in screening programs. Research shows that delays in endometriosis diagnosis disproportionately affect women’s quality of life and reproductive health, with average diagnostic delays exceeding eight years in the United Kingdom and up to 12 years in the United States.

A simple, accurate test could help bridge these gaps, particularly in underserved communities where access to specialized gynecological care may be limited.

Moving from laboratory proof-of-concept to clinical application will require additional validation studies, including testing with actual patient samples and comparison to existing diagnostic methods. The study did not report data on long-term stability or storage conditions, which are key factors for future clinical translation. However, the relatively simple manufacturing requirements and use of established lateral flow technology could facilitate faster development compared to more complex diagnostic platforms. The research represents a significant step forward in personalized women’s health, offering hope for earlier detection and treatment of a condition that has historically been underdiagnosed and undertreated.

Disclaimer: This article summarizes findings from a laboratory-based proof-of-concept study. The test has not yet been validated with real patient samples or approved for clinical use. Claims about sensitivity and specificity are based on spiked menstrual blood models, not diagnostic trials. Speculative discussion about future applications (e.g. integration into menstrual products) is not presented by the authors but is offered here as a potential implication based on the technology’s design. Readers should not interpret this research as evidence of an available commercial diagnostic product.

---